Market Overview - The Chinese medical device market is expected to grow to 1.66 trillion yuan by 2030, with significant growth potential in the medical consumables sector[2] - The global medical device industry reached a total scale of $47.936 billion in 2023, projected to grow to $63.796 billion by 2028[2][7] - By 2025, China's medical device market is anticipated to reach 1.2442 trillion yuan, with a compound annual growth rate (CAGR) of 14.76% from 2017 to 2024[9] Medical Consumables Insights - In 2024, the medical consumables market in China is expected to account for 63.18% of the total medical device market, with a market size of approximately 595 billion yuan[14] - The high-value medical consumables market in China grew from 60.2 billion yuan in 2015 to 250.4 billion yuan in 2024, reflecting a CAGR of 17.2%[15] - The vascular intervention consumables segment is the largest, projected to reach about 91.8 billion yuan in 2024, representing 36.7% of the high-value consumables market[15] Market Performance - The median stock price change for the North Exchange's consumer service sector was -3.78% from March 23 to March 27, 2026, with 7% of companies experiencing an increase[37] - The total market capitalization of the North Exchange consumer service sector decreased from 100.036 billion yuan to 95.322 billion yuan during the same period[41] - The median price-to-earnings (P/E) ratio for the North Exchange consumer service sector fell from 37.5X to 36.5X[40] Company Announcements - Yisheng Mushrooms reported a revenue of 739.29 million yuan for 2025, a year-on-year increase of 19.91%, but a net profit decline of 23.05%[54] - The company plans to distribute a cash dividend of 5.00 yuan per 10 shares, totaling approximately 51.52 million yuan[54]

Core Viewpoint - The company reported a decline in both revenue and net profit for the fiscal year 2025, indicating potential challenges in its financial performance and market position [1]. Financial Performance - Total revenue for the reporting period was 300,328,058.66 yuan, a year-on-year decrease of 12.85% [1]. - Net profit attributable to shareholders was 18,913,373.29 yuan, down 31.33% compared to the previous year [1]. - Net profit after deducting non-recurring gains and losses was 16,662,834.86 yuan, reflecting a 36.42% decline year-on-year [1]. - Basic earnings per share were 0.11 yuan, which is a 31.33% decrease from the prior year [1]. Asset and Equity Position - Total assets at the end of the reporting period amounted to 589,226,940.16 yuan, showing a year-on-year growth of 11.27% [1]. - Shareholder equity attributable to the company was 383,776,435.86 yuan, which represents a 4.00% decline compared to the previous year [1]. Stock Performance - As of the market close on February 27, 2026, the stock price was 9.51 yuan, down 1.25% from the previous trading day [1]. - The stock opened at 9.63 yuan, reached a high of 9.65 yuan, and a low of 9.47 yuan during the trading session [1]. - The trading volume for the day was 16,028,800 yuan, with a turnover rate of 2.27% [1].

Core Insights - The company reported a revenue of 300 million yuan for 2025, a decrease of 12.85% compared to 345 million yuan in the same period last year [1] - The net profit attributable to shareholders was 18.91 million yuan, down 31.33% from 27.54 million yuan in the previous year [1] Financial Performance - Revenue for 2025: 300 million yuan, down from 345 million yuan [1] - Net profit for 2025: 18.91 million yuan, down from 27.54 million yuan [1] - Year-on-year revenue decline: 12.85% [1] - Year-on-year net profit decline: 31.33% [1]

特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 证券代码：920278 证券简称：鹿得医疗 公告编号：2026-004 江苏鹿得医疗电子股份有限公司 2025 年年度业绩快报公 告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 1、经营情况： 报告期内，公司实现营业总收入预计为 300,328,058.66 元，同比下降 12.85%； 归属于上市公司股东的净利润预计为 18,913,373.29 元，同比下降 31.33%；归属 于上市公司股东的扣除非经常性损益的净利润预计为 16,662,834.86 元，同比下 降 36.42%；基本每股收益预计为 0.11 元，同比下降 31.33%。 2、财务状况： 报告期末，公司总资产预计为 589,226,940.16 元，同比增长 11.27%；归属于 上市公司股东的所有者权益预计为 383,776,435.86 元，同比下降 4 ...

Company Performance - The company has not yet announced its full-year financial data for 2025, with an annual report expected to be released in early 2026. The Q3 2025 report shows revenue of 216.5 million and a net profit of 17.69 million, with attention needed on whether losses will further narrow and the recovery of overseas sales [2]. Industry Policy and Environment - The national "14th Five-Year Plan" clearly supports the development of innovative drugs and medical devices, with the smart home medical device market expected to exceed 90 billion by 2026. This policy may provide growth opportunities for the company's products, such as blood pressure monitors and nebulizers. However, international geopolitical conflicts have impacted overseas revenue, which saw a year-on-year decline of 9.72% in the first half of 2025 [3]. Company Business Status - The company primarily focuses on overseas markets, with 87.42% of its revenue coming from international sales in 2019. Attention is needed on the expansion of cross-border e-commerce and the operational efficiency of the "Lude Medical Health Smart Industry Park Project." The H1 2025 report indicates that the company is promoting lean management and optimizing production lines to enhance capacity utilization [4].

Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the six-month moving average, with a change of -0.03% [1] - The total trading volume of A-shares today is 185.05 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 168 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Nearshore Protein (近岸蛋白) with a deviation rate of 19.69% and a price increase of 19.99% [1] - Erkang Pharmaceutical (尔康制药) with a deviation rate of 17.97% and a price increase of 19.14% [1] - Wanbang Pharmaceutical (万邦医药) with a deviation rate of 12.41% and a price increase of 12.85% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Bo Wen Technology (博闻科技) with a deviation rate just above the average [1] - Jilin Expressway (吉林高速) and Teda Investment (泰达股份) also show minor deviations [1] Additional Notable Stocks - Other stocks with notable performance include: - Deer Medical (鹿得医疗) with a price increase of 13.63% and a deviation rate of 11.86% [1] - Chuaning Biological (川宁生物) with a price increase of 12.84% and a deviation rate of 10.67% [1] - New Zhi Biological (新芝生物) with a price increase of 14.33% and a deviation rate of 10.66% [1]

Group 1 - The stock price of Lude Medical (920278) closed at 10.2 yuan on January 12, 2026, with an increase of 5.92% and a turnover rate of 21.14%, resulting in a trading volume of 156,500 shares and a transaction amount of 155 million yuan [1] - On January 12, 2026, the net inflow of main funds was 18.02 million yuan, accounting for 11.61% of the total transaction amount, while retail investors had a net outflow of 2.22 million yuan, representing 1.43% of the total transaction amount [1][3] - The company held its 13th meeting of the 4th Board of Directors on January 9, 2026, where it approved the postponement of the "Lude Medical Health Smart Industrial Park" fundraising project without changing the total investment amount or the use of raised funds [1] Group 2 - The "Lude Medical Health Smart Industrial Park" project has been delayed from the original expected completion date of February 7, 2026, to June 30, 2027, due to economic conditions and market demand [2][3] - As of December 31, 2025, the project had accumulated an investment of approximately 85.25 million yuan, with an investment progress of 72.81% [2]

Group 1 - The core point of the article is that Lude Medical (920278) has experienced a stock price increase of 5.92% to 10.2 yuan, with a total market capitalization of 1.78 billion yuan as of January 12, 2026 [1] - The stock opened at 9.81 yuan, reached a high of 10.24 yuan, and a low of 9.54 yuan, with a trading volume of 1.55 billion yuan and a turnover rate of 21.14% [1] - Lude Medical announced a delay in the construction progress of its "Lude Medical Health Smart Industrial Park" project due to economic conditions and market demand, pushing the expected completion date from February 7, 2026, to June 30, 2027 [1] - As of December 31, 2025, the project has utilized 85,249,547.09 yuan of raised funds, achieving an investment progress of 72.81% [1] - The decision regarding the project delay has been approved by the board of directors and relevant committees, with no objections from the sponsoring institution [1]

证券代码：920278 证券简称：鹿得医疗 公告编号：2026-002 江苏鹿得医疗电子股份有限公司部分募投项目延期公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 募集资金基本情况 2020 年 6 月 29 日，江苏鹿得医疗电子股份有限公司发行普通股 17,500,000 股，发行方式为不特定合格投资者公开发行，发行价格为 8.55 元/股，募集资金 总额为 149,625,000.00 元，募集资金净额为 138,770,570.99 元，到账时间为 2020 年 7 月 16 日。 二、 募集资金使用情况 截至 2025 年 12 月 31 日，公司上述发行股份的募集资金使用情况具体如下： | | | | | 募集资金计划 | 累计投入募集 | 投入进度（%） | | --- | --- | --- | --- | --- | --- | --- | | 序 | 募集资金用 | 实施 | | 投资总额（调整 | 资金金额 | （3）=（2）/ | | 号 | 途 | 主体 | | 后） ...